Publications
Detailed Information
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Keun Wook | - |
dc.contributor.author | Lee, Kyung-Hee | - |
dc.contributor.author | Sohn, Chang-Hak | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Ryoo, Hun-Mo | - |
dc.contributor.author | Song, Hong-Suk | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Kang, Hye-Jin | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:55:34Z | - |
dc.date.available | 2021-01-31T11:55:34Z | - |
dc.date.created | 2020-11-17 | - |
dc.date.issued | 2012-06 | - |
dc.identifier.citation | Investigational New Drugs, Vol.30 No.3, pp.1164-1174 | - |
dc.identifier.issn | 0167-6997 | - |
dc.identifier.other | 116427 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173140 | - |
dc.description.abstract | Background To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC). Methods Locally advanced PC was excluded. Erlotinib was given at a dose of 100 mg daily from D1 to D28. 1000 mg/m(2) of gemcitabine was given on D1,8,15 and 1660 mg/m(2)/day of capecitabine was given from D1 to 21, repeated every 4 weeks. Response was assessed every 8 weeks. Results A total of 47 patients were enrolled. Response rate and disease control rate was 32.6% (95% CI, 18.6-46.6%) and 83.7% (95% CI, 72.7-94.7%) respectively. The PFS was 6.5 months (95% CI, 3.4-9.7) and OS was 12.0 months (95% CI, 8.6-15.9). The Gr 3/4 toxicities were: neutropenia (6.8%), thrombocytopenia (3.2%), anemia (1.6%). nausea (1.6%), vomiting (1.6%), anorexia (5.3%), rash (2.4%). The EGFR expression was associated with shorter OS and ERCC2 expression was associated with longer PFS and OS. PFS and OS were not different according to K-RAS mutation or polymorphism of RRM1 and CDA. Conclusions Erlotinib, gemcitabine and capecitabine combination showed promising efficacy and good tolerability in metastatic PC. This efficacy was observed irrespective of K-RAS mutation, and EGFR expression was poor prognostic factor for OS. | - |
dc.language | 영어 | - |
dc.publisher | Kluwer Academic Publishers | - |
dc.title | A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1007/s10637-011-9651-3 | - |
dc.citation.journaltitle | Investigational New Drugs | - |
dc.identifier.wosid | 000303878700034 | - |
dc.identifier.scopusid | 2-s2.0-84864366235 | - |
dc.citation.endpage | 1174 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 1164 | - |
dc.citation.volume | 30 | - |
dc.identifier.sci | 000303878700034 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RECEPTOR INTRON-1 POLYMORPHISM | - |
dc.subject.keywordPlus | COOPERATIVE-ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | RIBONUCLEOTIDE REDUCTASE | - |
dc.subject.keywordPlus | PLUS GEMCITABINE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | PHARMACOGENETICS | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordAuthor | Erlotinib | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Capecitabine | - |
dc.subject.keywordAuthor | Pancreatic cancer | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | K-RAS | - |
dc.subject.keywordAuthor | EGFR | - |
dc.subject.keywordAuthor | ERCC2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.